These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 1081857

  • 1. The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report.
    Gordon BL, Keenan JP.
    Ann Allergy; 1975 Dec; 35(6):343-55. PubMed ID: 1081857
    [Abstract] [Full Text] [Related]

  • 2. [Effect of levamisole (Decaris) on various immunologic parameters in patients with systemic lupus erythematosus].
    Gandzha IM, Sakharchuk VM, Lysenko GI.
    Ter Arkh; 1981 Dec; 53(7):121-4. PubMed ID: 6457406
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months.
    Gordon BL, Yanagihara R.
    Ann Allergy; 1977 Oct; 39(4):227-36. PubMed ID: 71868
    [Abstract] [Full Text] [Related]

  • 4. Study of lymphocyte subpopulations in patients with systemic lupus erythematosus. In vitro effect of levamisole on T-lymphocyte population.
    Pozsonyi T, Jakab L, Fehér J.
    Allergol Immunopathol (Madr); 1980 Oct; 8(5):553-8. PubMed ID: 6970515
    [Abstract] [Full Text] [Related]

  • 5. [Clinical experience with levamisole treatment of patients with systemic lupus erythematosus (author's transl)].
    Scherak O, Smolen J, Kolarz G, Kojer M, Menzel J.
    Wien Klin Wochenschr; 1979 Nov 23; 91(22):758-62. PubMed ID: 160142
    [Abstract] [Full Text] [Related]

  • 6. [Diagnosis of T-immunodeficiencies in lupus erythematosus and patient treatment with levamisole].
    Shaposhnikov OK, Gorbunov VF.
    Vestn Dermatol Venerol; 1979 Mar 23; (3):3-6. PubMed ID: 311566
    [No Abstract] [Full Text] [Related]

  • 7. [Immunostimulant therapy of kidney diseases].
    Karastanev I.
    Vutr Boles; 1982 Mar 23; 21(3):8-13. PubMed ID: 6180558
    [No Abstract] [Full Text] [Related]

  • 8. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.
    Rheumatology (Oxford); 2005 Feb 23; 44(2):176-82. PubMed ID: 15494350
    [Abstract] [Full Text] [Related]

  • 9. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.
    Huang YP, Perrin LH, Miescher PA, Zubler RH.
    J Immunol; 1988 Aug 01; 141(3):827-33. PubMed ID: 3135313
    [Abstract] [Full Text] [Related]

  • 10. Systemic lupus erythematosus in children: current and emerging therapies.
    Macdermott EJ, Adams A, Lehman TJ.
    Lupus; 2007 Aug 01; 16(8):677-83. PubMed ID: 17711907
    [Abstract] [Full Text] [Related]

  • 11. B cell activity and regulatory T cell function in systemic lupus erythematosus by human B cell colony formation.
    Otsuka T, Okamura S, Niho Y, Kusaba T.
    J Rheumatol; 1985 Jun 01; 12(3):508-13. PubMed ID: 2864442
    [Abstract] [Full Text] [Related]

  • 12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG, Jones RB, Burns SM, Jayne DR.
    Arthritis Rheum; 2006 Sep 01; 54(9):2970-82. PubMed ID: 16947528
    [Abstract] [Full Text] [Related]

  • 13. Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease.
    Ramot B, Biniaminov M, Shoham C, Rosenthal E.
    N Engl J Med; 1976 Apr 08; 294(15):809-11. PubMed ID: 1082545
    [Abstract] [Full Text] [Related]

  • 14. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus.
    Dau PC, Callahan J, Parker R, Golbus J.
    J Rheumatol; 1991 Feb 08; 18(2):270-6. PubMed ID: 1827161
    [Abstract] [Full Text] [Related]

  • 15. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A, White AJ.
    Autoimmun Rev; 2006 Jan 08; 5(1):18-24. PubMed ID: 16338207
    [Abstract] [Full Text] [Related]

  • 16. The in vitro effect of levamisole on histamine inhibited E-rosette forming T-lymphocyte subpopulation in patients affected by disseminated erythematosus lupus.
    Pozsonyi T, Jakab L, Fehér J, Cseh K.
    Allergol Immunopathol (Madr); 1982 Jan 08; 10(6):435-9. PubMed ID: 6220589
    [Abstract] [Full Text] [Related]

  • 17. [Levamisole -- a drug modifying immunologic phenomena].
    Bogdanikowa B.
    Postepy Hig Med Dosw; 1979 Jan 08; 33(2):125-46. PubMed ID: 384382
    [No Abstract] [Full Text] [Related]

  • 18. Levamisole treatment of recurrent spastic bronchitis in children--the effect on selected parameters of immunologic and hemostatic systems.
    Prusek W, Wieczorek E, Podwysocka M, Maćkowiak J.
    Arch Immunol Ther Exp (Warsz); 1985 Jan 08; 33(6):803-9. PubMed ID: 3914252
    [Abstract] [Full Text] [Related]

  • 19. Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus.
    Messner RP, Lindström FD, Williams RC.
    J Clin Invest; 1973 Dec 08; 52(12):3046-56. PubMed ID: 4584345
    [Abstract] [Full Text] [Related]

  • 20. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
    Stanislav ML, Balabanova RM, Nikonova MF, Litvina MM, Iarilin AA.
    Ter Arkh; 2000 Dec 08; 72(5):44-9. PubMed ID: 11109620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.